[go: up one dir, main page]

TN2009000442A1 - Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 - Google Patents

Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90

Info

Publication number
TN2009000442A1
TN2009000442A1 TNP2009000442A TN2009000442A TN2009000442A1 TN 2009000442 A1 TN2009000442 A1 TN 2009000442A1 TN P2009000442 A TNP2009000442 A TN P2009000442A TN 2009000442 A TN2009000442 A TN 2009000442A TN 2009000442 A1 TN2009000442 A1 TN 2009000442A1
Authority
TN
Tunisia
Prior art keywords
nucleic acids
antibody molecules
stress protein
novel antibody
protein hsp90
Prior art date
Application number
TNP2009000442A
Other languages
English (en)
Inventor
James Burnie
Philipp Wechner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000442A1 publication Critical patent/TN2009000442A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TNP2009000442A 2007-04-27 2009-10-23 Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 TN2009000442A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07107140 2007-04-27
EP07113353 2007-07-27
PCT/EP2008/055006 WO2008132134A1 (fr) 2007-04-27 2008-04-24 Nouvelles molécules d'anticorps et d'acides nucléiques se fixant à la protéine hsp90 de stress fongique

Publications (1)

Publication Number Publication Date
TN2009000442A1 true TN2009000442A1 (en) 2011-03-31

Family

ID=39717534

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000442A TN2009000442A1 (en) 2007-04-27 2009-10-23 Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90

Country Status (21)

Country Link
US (3) US20100113355A1 (fr)
EP (2) EP2144932A1 (fr)
JP (1) JP2010524485A (fr)
KR (1) KR20100017387A (fr)
CN (1) CN101679517A (fr)
AR (1) AR066311A1 (fr)
AU (1) AU2008244308A1 (fr)
BR (1) BRPI0810827A2 (fr)
CA (1) CA2685136A1 (fr)
CL (1) CL2008001202A1 (fr)
CR (1) CR11059A (fr)
EA (1) EA200901441A1 (fr)
EC (1) ECSP099765A (fr)
GT (1) GT200900276A (fr)
IL (1) IL201445A0 (fr)
MA (1) MA31384B1 (fr)
MX (1) MX2009011595A (fr)
PE (1) PE20090728A1 (fr)
TN (1) TN2009000442A1 (fr)
TW (1) TW200902714A (fr)
WO (2) WO2008132134A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
ES2830392T3 (es) * 2014-07-23 2021-06-03 Ohio State Innovation Foundation Métodos y composiciones relacionados con fragmentos de anticuerpo que se unen a la glicoproteína 72 asociada a tumores (TAG-72)
CN105652011B (zh) * 2014-11-20 2017-09-22 深圳市安群生物工程有限公司 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法
CN113845591B (zh) * 2018-10-30 2023-10-31 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732852A (en) * 1981-11-20 1988-03-22 Cetus Corporation Site directed peptidase cleavage
US4670382A (en) 1983-12-02 1987-06-02 Temple University--of the Commonwealth System of Higher Education Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same
US4806465A (en) * 1984-01-16 1989-02-21 Temple University Of The Commonwealth System Of Higher Education Cytoplasmic antigens of candida albicans and methods of using the same
GB8506373D0 (en) 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
CA2370007A1 (fr) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Procedes et compositions permettant la degradation et/ou l'inhibition des tyrosine kinases appartenant a la famille her
JP3929777B2 (ja) 2000-01-25 2007-06-13 オクラホマ メディカル リサーチ ファウンデーション 組換えタンパク質をリフォールディングするための凡用的な手順
GB0008305D0 (en) 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
WO2002006990A1 (fr) 2000-07-14 2002-01-24 Healthcite, Inc. Procede et systeme pour fournir des informations medicales
US20060079493A1 (en) 2001-03-01 2006-04-13 Lawrence Fritz Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors
GB0127983D0 (en) 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0409077D0 (en) * 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
US20080038267A1 (en) * 2004-07-02 2008-02-14 Neutec Pharma Limited Treatment Of Cancer
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (fr) 2007-04-27 2008-11-06 Novartis Ag Composition d'immunoglobulines

Also Published As

Publication number Publication date
EP2144932A1 (fr) 2010-01-20
JP2010524485A (ja) 2010-07-22
BRPI0810827A2 (pt) 2014-10-29
PE20090728A1 (es) 2009-07-02
EA200901441A1 (ru) 2010-04-30
AU2008244308A1 (en) 2008-11-06
US20090136484A1 (en) 2009-05-28
WO2008132134A1 (fr) 2008-11-06
IL201445A0 (en) 2010-06-16
ECSP099765A (es) 2009-12-28
CA2685136A1 (fr) 2008-11-06
CR11059A (es) 2009-11-20
MA31384B1 (fr) 2010-05-03
US20100166758A1 (en) 2010-07-01
TW200902714A (en) 2009-01-16
US20100113355A1 (en) 2010-05-06
WO2008132152A1 (fr) 2008-11-06
AR066311A1 (es) 2009-08-12
KR20100017387A (ko) 2010-02-16
CL2008001202A1 (es) 2008-12-19
US7722869B2 (en) 2010-05-25
WO2008132134A9 (fr) 2009-07-09
MX2009011595A (es) 2009-12-08
GT200900276A (es) 2010-05-21
CN101679517A (zh) 2010-03-24
EP2152746A1 (fr) 2010-02-17

Similar Documents

Publication Publication Date Title
TN2009000442A1 (en) Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
EP2987806A3 (fr) Anticorps modifiés à domaine variable unique présentant une diminution de liaison pour des anticorps anti-médicament
NZ597692A (en) Anti-IGF antibodies
NZ612319A (en) Single-chain multivalent binding proteins with effector function
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2005051998A3 (fr) Anticorps
EP3670536A3 (fr) Polypeptides d'élément de la famille des ligands tnf recombinants avec domaine de liaison d'anticorps et utilisations associées
HK1214605A1 (zh) 具有抗肿瘤活性的新颖的双特异性结合分子
WO2008005880A3 (fr) Anticorps anti-norovirus
PE20120001A1 (es) Dominios variables simples anti-albumina de suero mejorados
WO2008114149A3 (fr) Antigènes chimériques
WO2008048545A3 (fr) Molécules ayant des demi-vies réduites, compositions et leurs utilisations
NZ600278A (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2003070760A3 (fr) Anticorps anti-a$g(b) et leur utilisation
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
WO2009004822A1 (fr) ANTICORPS ANTI-Muc17
WO2014090905A8 (fr) Protéines modifiées à superhélice et à propriétés améliorées
MX2010000994A (es) Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6, dominio dimerico, metodo de inmunizacion, metodo de deteccion de rotavirus, composicion, metodos de prevencion y tratamiento de infecciones con rotavirus.
EP4269562A3 (fr) Molécules de liaison à l'antigène et procédés d'utilisation associés
ATE490270T1 (de) Zytokinderivate
WO2008039838A3 (fr) Vaccin synthetique contre le streptococcus pneumoniae
WO2004108749A3 (fr) Nouveaux peptides de liaison, leurs procedes de production et d'utilisation
WO2008142664A3 (fr) Peptides exposés associés à la prolifération, ligands et procédés mettant en œuvre de tels peptides
AR082160A1 (es) Anticuerpos monoclonales dirigidos contra la toxina tetanica
WO2009060710A1 (fr) Peptide conférant une aptitude de liaison à un anticorps à des liposomes et liposome modifié par ce peptide